CA
NZ
UK
AU
IND
US
The biopharmaceutical firm concluded the quarter with $176.4 million in cash, cash equivalents, and marketable securities, which is projected to fund its operations into 2029. This financial stability is important as the company progresses its next-generation PI3Kα pan-mutant selective inhibitor programs, OKI-345 and OKI-355, …
OrthoPediatrics Corp (NASDAQ: KIDS) posted a remarkable Q2 2026 revenue of $70.5 million, representing a solid 15% increase from $61.1 million in the same quarter last year. This performance surpassed analysts' expectations, as the company reported a loss per share of $-0.26, better than …
The company's earnings per share (EPS) also beat analysts' expectations, coming in at $0.73 against a consensus estimate of $0.66. This strong performance underscores the ongoing demand for Pacira’s innovative pain management solutions, enhancing its appeal to investors who prioritize growth in the healthcare …
PACS Group reported adjusted earnings per share of $0.63 for the quarter ended June 30, outpacing the $0.55 consensus estimate. Investors see the beat as evidence that the company’s operating model and acquisition strategy are delivering measurable profit acceleration.
Palvella Therapeutics, Inc. (NASDAQ: PVLA) reported a hefty net loss of $21.9 million, equating to $1.52 per share, for the quarter ending June 30, 2026. The company’s ongoing expenditures are linked to the advancement of novel therapies for rare skin diseases. Investors now grapple …
Pfizer Inc. (NYSE: PFE) reported its second-quarter results for 2026, announcing a significant revision of its revenue guidance, now projecting a range of $60.5 billion to $62.5 billion. This marks a $500 million increase from previous estimates, responding to stronger demand for its portfolio …
Pfizer Inc. (NYSE: PFE) achieved second-quarter revenues of $15 billion, a 3% increase compared to the previous year, and surpassed analyst expectations. This result led the pharmaceutical giant to adjust its 2026 revenue guidance upward by $500 million, now targeting between $60.5 billion and …
Novo Nordisk A/S has raised its forecast, but the stock has come under pressure, reflecting a growing concern regarding its viability in the obesity treatment market. Following a reported earnings per share (EPS) of $6.63 for the quarter ended March 31, exceeding consensus estimates …
Nuvectis Pharma, Inc. (NASDAQ: NVCT) enhanced its financial footing by successfully raising $115 million in a follow-on offering completed in July 2026. This substantial funding lowers liquidity challenges and supports its urgent development agenda, particularly for its lead drug candidate, ciprocopan (NXP100), which has …
Odyssey Therapeutics, Inc. reported a substantial net loss of $52.8 million in its second quarter ended June 30, 2026, significantly greater than the $41.2 million loss recorded during the same period in the previous year. The reported earnings per share (EPS) of $-6.77 also …
Please wait processing your request...